This week, we round out our discussion on metastatic colorectal cancer, focusing on more targeted therapies for this disease. If you have not done so already, be sure to check out episode 107 for the first part of our metastatic colorectal cancer discussion.
Contents:
- What is the role of immunotherapy?
- What is the role of BRAF inhibition?
- Can we use ... Show More
Sep 17
Episode 139: Follicular Lymphoma Series, Pt 4 - Relapsed/Refractory Management (Cellular therapy options)
<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;"><strong>This week, we continue talking about relapsed/refractory follicular lymphoma, this time focusing on cellular therapy options, namely bispecific agents and CAR T therapy. If you have not done so, we h ... Show More
36m 11s
Sep 10
Episode 138: Follicular Lymphoma Series, Pt 3 - Relapsed/Refractory Management (non-cellular therapy options)
<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;"><strong>This week, we shift our focus to talking about relapsed/refractory follicular lymphoma. In this episode, we will specifically discuss treatment options other than cellular therapy, which will be an u ... Show More
29m 51s
Jun 2025
Episode 137: Follicular Lymphoma Series, Pt 2. - Front-line Management
<p class="" data-rte-preserve-empty="true" style="white-space:pre-wrap;">This week, we continue our conversation on follicular lymphoma, this time focusing on front line therapy. We discuss how we approach localized and diffuse disease and the data behind why we do what we do. </ ... Show More
30m 11s
Dec 2024
141. Back to Basics - The role of endocrine therapy in Breast Cancer
<p>Before immunotherapy, targeted chemotherapy (ADCs) and precision oncology, there was endocrine therapy, the forefather (or mother) of effective treatment to reduce breast cancer recurrence as well as delay disease progression. This episode dives into a past of phenomenal impro ... Show More
24m 4s
Dec 2024
139. Back to Basics - Early HER2 Breast Cancer
<p>Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, including breast, gastric, colorectal, and epithelial ovarian cancers. However, this receptor's complexity doesn't stop there. It has multiple subdomains and various responses to drugs, and t ... Show More
24m 31s